help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on October 12, 2006
Endocrinology, doi:10.1210/en.2006-0460
A more recent version of this article appeared on January 1, 2007
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
148/1/422    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by LATCHOUMANIN, O.
Right arrow Articles by CATELLI, M. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by LATCHOUMANIN, O.
Right arrow Articles by CATELLI, M. G.

Submitted on April 10, 2006
Accepted on October 4, 2006

Reversal of glucocorticoids-dependent POMC gene inhibition by Leukemia Inhibitory Factor

OLIVIER LATCHOUMANIN, VANESSA MYNARD, JOCELYNE DEVIN-LECLERC, MARIE-ANNICK DUGUE, XAVIER BERTAGNA, and MARIA GRAZIA CATELLI*

Institut Cochin, Département d'Endocrinologie, Métabolisme et Cancer, Paris, F-75014 France; INSERM, U567, Paris, F-75014 France; CNRS, UMR8104, Paris, F-75014 France; Université Paris 5, Faculté de Médecine René Descartes, UM3, Paris, F-75014 France

* To whom correspondence should be addressed. E-mail: catelli{at}cochin.inserm.fr.

We have previously described molecular mechanisms converging at the NurRE-STAT composite site responsible for synergistic activation of the POMC gene promoter by LIF and CRH. Here, we asked how glucocorticoids (GC), the physiological negative regulators of POMC gene expression, modulate this synergism.

In the corticotroph cell line AtT-20, the response of the wild-type promoter to LIF+CRH was barely inhibited by GC, whereas a distal promoter subregion (-414/-293) encompassing the NurRE-STAT site and devoid of the negative GRE (nGRE) located in the proximal domain, displayed a cooperative response to LIF+DEX and LIF+CRH+DEX treatments. LIF+CRH-stimulated ACTH secretion was also inefficiently inhibited by DEX in the same cell line. This study was thereafter focused on LIF+DEX cooperativity, which may be responsible, on the wild-type promoter, for lack of negative regulation by DEX of the LIF+CRH synergy. The STAT1-3 low affinity site, in the context of the (-414/-293) subregion of the POMC promoter, was found necessary and sufficient for transcriptional synergism between activated glucocorticoid receptor (GR) and STAT1-3. Moreover the activities of reporters specific for STAT1-3 or GR were reciprocally enhanced by DEX or LIF.

Single and sequential chromatin immunoprecipitations (ChIP) revealed 1) a STAT-dependent co-recruitment of coactivators after LIF and LIF+DEX stimulation and 2) a more lasting recruitment of both STAT3 and GR in the same enhanceosome on the endogenous POMC promoter after LIF+DEX joint stimulation than after the single one. Such events may be responsible for a lack of repressive property of GR unmasked on the whole POMC promoter during LIF+CRH stimulation and may contribute to the tonicity of the HPA axis during inflammatory-infectious diseases.


Key words: STAT1-3 • LIF • glucocorticoid receptor • transcriptional activation • POMC promoter







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2006 by The Endocrine Society